Western blot analysis of extracts from RAW 264.7 cells, untreated (-) or treated with Resiquimod (R-848) (1 μg/ml, 15 min; +), using Phospho-SAPK/JNK (Thr183/Tyr185) (G9) Mouse mAb #9255 (upper) or SAPK/JNK Antibody #9252 (lower).
Chemical structure of Resiquimod (R-848).
Resiquimod (R-848) is supplied as a lyophilized powder. For a 15 mM stock, reconstitute 5 mg of powder in 1.06 ml of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 2 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
Molecular Weight: 314.4 g/mol
Molecular Formula: C17H22N4O2
Solubility: Soluble in DMSO at 30 mg/ml and ethanol at 15 mg/ml with slight warming.
Resiquimod (R-848), an antiviral imidazoquinoline, has been shown to activate Toll-like receptor 7 (TLR7) and TLR8 via the MyD88-dependent interleukin 1 receptor (IL-1R)-TLR signaling pathway (1). Triggering of the TLR pathway leads to the activation of NF-κB and subsequent regulation of immune and inflammatory genes (2). Similar to CD40, treatment with Resiquimod (R-848) activates B cells and can induce nuclear translocation of NF-κB at a concentration of 1 μg/ml (3).
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.